Current Issues in Pharmacoeconomic Modeling

키워드

참고문헌 (19)

1. Hay JW, "Evaluation and review of pharmacoeconomic models", Expert Opin Pharmacother, 5, pp.1867~1880 (2004)
2. Hay JW, "Using pharmacoeconomics to value pharmacotherapy", Clin Pharmacol Ther, 84, pp.197~200 (2008)
3. Sutton A, "Use of indirect and mixed treatment comparisons for technology assessment", Pharmacoeconomics, 26, pp.753~767 (2008)
4. Song F, "Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses", BMJ, 326, pp.472~ (2003)
5. Leonardi CL, "Etanercept as monotherapy in patients with psoriasis", N Engl J Med, 349, pp.2014~2022 (2003)
6. Papp KA, "Efficacy and safety of ustekinumab, a human interleukin-12", 23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), 2008, pp.371, 1675~1684
7. Villacorta R, "Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States", Pharmacoeconomics, 31, pp.823~839 (2013)
8. Song F, "Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study", BMJ, 343, pp.d4909~ (2011)
9. Lumley T, "Network meta-analysis for indirect treatment comparisons", Stat Med, 21, pp.2313~2324 (2002)
10. Lu G, "Combination of direct and indirect evidence in mixed treatment comparisons", Stat Med, 23, pp.3105~3124 (2004)
11. Louviere JJ, "Discrete choice experiments are not conjoint analysis", J Choice Model, 3, pp.57~72 (2010)
12. Hay JW, "Conjoint analysis in pharmaceutical research", J Manag Care Pharm, 8, pp.206~207 (2002)
13. Louviere JJ, "Stated choice methods: analysis and applications" (2000), Cambridge University Press
14. Ryan M, "Using discrete choice experiments to value health care programmes: current practice and future research reflections", Appl Health Econ Health Policy, 2, pp.55~64 (2003)
15. de Bekker-Grob EW, "Discrete choice experiments in health economics: a review of the literature", Health Econ, 21, pp.145~172 (2012)
16. Hay JW, "Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor", moderate bleeding episodes for haemophilia patients with inhibitors, 2010, pp.16, 366~368
17. Hay JW, "Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa", J Med Econ, 14, pp.516~525 (2011)
18. Caro JJ, "Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1", Med Decis Making, 32, pp.667~677 (2012)
19. Ginnelly L, "Using value of information analysis to inform publicly funded research priorities", Appl Health Econ Health Policy, 4, pp.37~46 (2005)

관련 논문AI추천